Medtronic wins FDA nod to deliver PAH therapy with implantable pump

Medtronic (NYSE:MDT) said today that it won FDA approval for its implantable drug-delivery system designed to administer United Therapeutics‘ (NSDQ:UTHR) pulmonary arterial hypertension drug, Remodulin.

United Therapeutics is slated to take the lead on commercial promotion of the drug-device system, with support from Medtronic.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic wins FDA nod to deliver PAH therapy with implantable pump appeared first on MassDevice.

from MassDevice https://ift.tt/2Ayqd4u